CYPOA Stock Overview
Develops and commercializes proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Cynata Therapeutics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.016 |
| 52 Week High | AU$0.017 |
| 52 Week Low | AU$0.01 |
| Beta | 0.81 |
| 11 Month Change | -5.88% |
| 3 Month Change | 6.67% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 60.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| CYPOA | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | -5.9% | 0.1% | 0.2% |
| 1Y | n/a | 6.9% | 7.5% |
Return vs Industry: Insufficient data to determine how CYPOA performed against the Australian Biotechs industry.
Return vs Market: Insufficient data to determine how CYPOA performed against the Australian Market.
Price Volatility
| CYPOA volatility | |
|---|---|
| CYPOA Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.8% |
| Market Average Movement | 8.3% |
| 10% most volatile stocks in AU Market | 16.7% |
| 10% least volatile stocks in AU Market | 3.3% |
Stable Share Price: CYPOA has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine CYPOA's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | n/a | Kilian Kelly | www.cynata.com |
Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company’s lead therapeutic product candidate is CYP-001, which has completed Phase I clinical trial for the treatment of graft versus host disease. It also develops CYP-004, which is in Phase III clinical trial used for the treatment of osteoarthritis; and CYP-006TK, a novel polymercoated silicon wound dressing for diabetic wounds.
Cynata Therapeutics Limited Fundamentals Summary
| CYPOA fundamental statistics | |
|---|---|
| Market cap | AU$23.35m |
| Earnings (TTM) | -AU$14.28m |
| Revenue (TTM) | AU$1.65m |
14.1x
P/S Ratio-1.6x
P/E RatioIs CYPOA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CYPOA income statement (TTM) | |
|---|---|
| Revenue | AU$1.65m |
| Cost of Revenue | AU$0 |
| Gross Profit | AU$1.65m |
| Other Expenses | AU$15.93m |
| Earnings | -AU$14.28m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.079 |
| Gross Margin | 100.00% |
| Net Profit Margin | -863.05% |
| Debt/Equity Ratio | 0% |
How did CYPOA perform over the long term?
See historical performance and comparison